What price ranges are disclosed for the Dyne Therapeutics share sales?

Footnotes describe weighted average prices with ranges. One group of transactions occurred between $21.00 and $21.50, another between $21.00 and $21.13, and a third between $21.00 and $21.255, reflecting multiple trades within narrow intraday bands.

Atlas funds tied to Dyne director sell 267,760 shares

Dyne Therapeutics, Inc. director-affiliated investment funds reported open-market sales of a total of 267,760 shares of Common Stock over June 23–25, 2026.

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Dyne Therapeutics, Inc. director-affiliated investment funds reported open-market sales of a total of 267,760 shares of Common Stock over June 23–25, 2026. The trades were executed at weighted average prices around $21 per share, with reported ranges from $21.00 to $21.50.

According to the footnotes, the shares are held indirectly through Atlas Venture entities, including Atlas Venture Fund XI and Atlas Venture Opportunity Funds I and II, as well as AVA XI LP. The filing states the sales were made under a Rule 10b5-1 trading plan adopted on March 19, 2026, and that Jason P. Rhodes disclaims Section 16 beneficial ownership in these funds beyond any pecuniary interest.

Insider Trade Summary 10b5-1

Net Seller: 267,760 shares

Net Sell 10 txns

Insider Rhodes Jason P

Role Director

Sold 267,760 shs ($5.65M)

Type	Security	Shares	Price	Value
Sale	Common Stock	12,699	$21.10	$268K
Sale	Common Stock	6,382	$21.10	$135K
Sale	Common Stock	5,019	$21.10	$106K
Sale	Common Stock	50,530	$21.02	$1.06M
Sale	Common Stock	25,397	$21.02	$534K
Sale	Common Stock	19,973	$21.02	$420K
Sale	Common Stock	77,855	$21.13	$1.65M
Sale	Common Stock	39,131	$21.13	$827K
Sale	Common Stock	30,774	$21.13	$650K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,089,006 shares (Indirect, See footnote)

Footnotes (8)

F1. Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.
F2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2), (6) and (7).
F3. The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any.
F4. The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.
F5. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
F6. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.13 inclusive.
F7. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.255 inclusive.
F8. The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any.

Key Figures

Shares sold: 267,760 shares Sale price (June 24 group): $21.02 per share Sale price (June 25 group): $21.10 per share +4 more

7 metrics

Shares sold 267,760 shares Total open-market sales over June 23–25, 2026

Sale price (June 24 group) $21.02 per share Weighted average price for one day’s transactions

Sale price (June 25 group) $21.10 per share Weighted average price for June 25, 2026 sales

Sale price (June 23 group) $21.13 per share Weighted average price for June 23, 2026 sales

Price range (footnote set 1) $21.00–$21.50 Multiple trades within this band as disclosed

Price range (footnote set 2) $21.00–$21.13 Additional trades executed in this range

Price range (footnote set 3) $21.00–$21.255 Further trades within this narrower band

Key Terms

Rule 10b5-1 trading plan, Section 16 beneficial ownership, weighted average price, indirect ownership, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Section 16 beneficial ownership regulatory

"disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein"

weighted average price financial

"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirect ownership financial

"The shares are held directly by Atlas Venture Fund XI, L.P. ... The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership"

open-market sale financial

"transaction_action": "open-market sale", "transaction_code_description": "Sale in open market or private transaction""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Dyne Therapeutics (DYN) Form 4 by Jason P. Rhodes report?

The Form 4 reports that funds affiliated with director Jason P. Rhodes sold 267,760 shares of Dyne Therapeutics common stock in open-market transactions, executed over June 23–25, 2026, at weighted average prices around $21 per share.

How many Dyne Therapeutics shares were sold and at what prices?

Associated Atlas Venture funds sold 267,760 Dyne Therapeutics common shares. Reported weighted average prices were about $21.02, $21.10 and $21.13 per share, with individual trade prices ranging from $21.00 up to $21.50, according to the filing’s detailed footnotes.

Were the Dyne Therapeutics insider sales made under a Rule 10b5-1 plan?

Yes. The filing states the shares were sold under a Rule 10b5-1 trading plan adopted on March 19, 2026. Such plans pre-schedule trades, indicating the timing of these sales was set in advance rather than decided opportunistically.

Who actually holds the Dyne Therapeutics shares involved in this Form 4?

The shares are held indirectly through Atlas Venture entities, including Atlas Venture Fund XI, Atlas Venture Opportunity Fund I and II, and AVA XI LP. The filing notes Jason P. Rhodes is a member of related general partners but holds only a pecuniary interest.

Does Jason P. Rhodes claim full beneficial ownership of the Dyne shares sold?

No. The Form 4 explicitly states Rhodes disclaims Section 16 beneficial ownership of securities held by the Atlas Venture funds, except to the extent of his pecuniary interest. This means the positions belong to the funds, not to him personally.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/26/2026 - 08:40 AM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rhodes Jason P

(Last)

(First)

(Middle)

C/O DYNE THERAPEUTICS, INC.

830 WINTER ST.

(Street)

WALTHAM

MASSACHUSETTS

02451

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dyne Therapeutics, Inc. [ DYN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/23/2026		S⁽¹⁾		77,855	D	$21.13⁽²⁾	4,805,639	I	See footnote⁽³⁾
Common Stock	06/23/2026		S⁽¹⁾		39,131	D	$21.13⁽²⁾	1,510,157	I	See footnote⁽⁴⁾
Common Stock	06/23/2026		S⁽¹⁾		30,774	D	$21.13⁽²⁾	1,106,036	I	See footnote⁽⁵⁾
Common Stock	06/24/2026		S⁽¹⁾		50,530	D	$21.02⁽⁶⁾	4,755,109	I	See footnote⁽³⁾
Common Stock	06/24/2026		S⁽¹⁾		25,397	D	$21.02⁽⁶⁾	1,484,760	I	See footnote⁽⁴⁾
Common Stock	06/24/2026		S⁽¹⁾		19,973	D	$21.02⁽⁶⁾	1,086,063	I	See footnote⁽⁵⁾
Common Stock	06/25/2026		S⁽¹⁾		12,699	D	$21.1⁽⁷⁾	4,742,410	I	See footnote⁽³⁾
Common Stock	06/25/2026		S⁽¹⁾		6,382	D	$21.1⁽⁷⁾	1,478,378	I	See footnote⁽⁴⁾
Common Stock	06/25/2026		S⁽¹⁾		5,019	D	$21.1⁽⁷⁾	1,081,044	I	See footnote⁽⁵⁾
Common Stock								7,962	I	See footnote⁽⁸⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.

2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2), (6) and (7).

3. The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any.

4. The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.

5. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.

6. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.13 inclusive.

7. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $21.00 to $21.255 inclusive.

8. The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any.

	/s/ Ommer Chohan, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR